This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simon, A. Articles by Levenson, J. Search for Related Content PubMed PubMed Citation Articles by Simon, A. Articles by Levenson, J.

(Circulation. 1997;96:2449-2452.)
© 1997 American Heart Association, Inc.

Articles

Coronary Risk Estimation and Treatment of Hypercholesterolemia

Alain Simon, MD; Jean Louis Megnien, MD; ; Jaime Levenson, MD

From the Centre de Médecine Préventive Cardiovasculaire, CR Inserm, Hôpital Broussais, Paris, France.

Background Evidence-based treatment of hypercholesterolemia currently recommended for rationalizing drug prescription requires justification of treatment by randomized trials, such as the West of Scotland Coronary Prevention Study (WOSCOPS) or the Scandinavian Simvastatin Survival Study (4S), and evaluation of its benefit from the estimation of the coronary risk of each patient.

Methods and Results The latest European guidelines and Sheffield tables apply these principles and justify the decision to treat hypercholesterolemia if the Framingham coronary multivariate risk estimate is high enough, ie, >20% risk of coronary event at 10 years in the former and >1.5% risk of coronary death per year in the latter. Nevertheless, the practice of these two recent guidelines results in discrepancies in the decision to treat, because coronary morbidity was considered in one but mortality was considered in the other, and the risk required for treating may be extrapolated from different trials (4S or WOSCOPS).

Conclusions Although the principle of targeting lipid-lowering treatment to high-risk subjects is unquestioned, further studies are needed to demonstrate that the Framingham risk profile is useful in selecting persons who are likely to benefit and to determine the place of newer risk factors and that of early noninvasive detection of atheroma in the risk estimation–based treatment.

Key Words: atherosclerosis • hypercholesterolemia • lipids • risk factors

This article has been cited by other articles:

				G. Chironi, A. Simon, B. Hugel, M. Del Pino, J. Gariepy, J.-M. Freyssinet, and A. Tedgui Circulating Leukocyte-Derived Microparticles Predict Subclinical Atherosclerosis Burden in Asymptomatic Subjects Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2775 - 2780. [Abstract] [Full Text] [PDF]

				P. Poredos Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis Vascular Medicine, February 1, 2004; 9(1): 46 - 54. [Abstract] [PDF]

				R. Scalia, M. E. Gooszen, S. P. Jones, M. Hoffmeyer, D. M. Rimmer III, S. D. Trocha, P. L. Huang, M. B. Smith, A. M. Lefer, and D. J. Lefer Simvastatin Exerts Both Anti-inflammatory and Cardioprotective Effects in Apolipoprotein E-Deficient Mice Circulation, May 29, 2001; 103(21): 2598 - 2603. [Abstract] [Full Text] [PDF]

				L. Papoz, A. Ponton, P. Segond, F. Becker, L. Drouet, J. Levenson, M. Marazanof, Y. Sentou, E. Chollet, J. Etiemble, et al. Feasibility and Reliability of Ankle/Arm Blood Pressure Index in Preventive Medicine Angiology, June 1, 2000; 51(6): 463 - 471. [Abstract] [PDF]

				P. Greenland, S. Grundy, R. C. Pasternak, and C. Lenfant Problems on the Pathway From Risk Assessment to Risk Reduction Circulation, May 19, 1998; 97(18): 1761 - 1762. [Full Text] [PDF]

				J. Gariepy, J. Salomon, N. Denarie, F. Laskri, J. L. Megnien, J. Levenson, and A. Simon Sex and Topographic Differences in Associations Between Large-Artery Wall Thickness and Coronary Risk Profile in a French Working Cohort : The AXA Study Arterioscler Thromb Vasc Biol, April 1, 1998; 18(4): 584 - 590. [Abstract] [Full Text] [PDF]